AU2005206410A1 - Method of producing minus strand RNA virus vector with the use of hybrid promoter containing cytomegalovirus enhancer and avian beta-actin promoter - Google Patents

Method of producing minus strand RNA virus vector with the use of hybrid promoter containing cytomegalovirus enhancer and avian beta-actin promoter Download PDF

Info

Publication number
AU2005206410A1
AU2005206410A1 AU2005206410A AU2005206410A AU2005206410A1 AU 2005206410 A1 AU2005206410 A1 AU 2005206410A1 AU 2005206410 A AU2005206410 A AU 2005206410A AU 2005206410 A AU2005206410 A AU 2005206410A AU 2005206410 A1 AU2005206410 A1 AU 2005206410A1
Authority
AU
Australia
Prior art keywords
rna
virus
dna
minus
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005206410A
Other languages
English (en)
Inventor
Hiroshi Ban
Mamoru Hasegawa
Takahiro Hirata
Akihiro Iida
Makoto Inoue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dnavec Research Inc
Original Assignee
Dnavec Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dnavec Research Inc filed Critical Dnavec Research Inc
Publication of AU2005206410A1 publication Critical patent/AU2005206410A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/90—Vector systems having a special element relevant for transcription from vertebrates avian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
AU2005206410A 2004-01-22 2005-01-20 Method of producing minus strand RNA virus vector with the use of hybrid promoter containing cytomegalovirus enhancer and avian beta-actin promoter Abandoned AU2005206410A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004-014653 2004-01-22
JP2004014653 2004-01-22
PCT/JP2005/000705 WO2005071092A1 (ja) 2004-01-22 2005-01-20 サイトメガロウイルスエンハンサーおよびニワトリβ-アクチンプロモーターを含むハイブリッドプロモーターを利用したマイナス鎖RNAウイルスベクターの製造方法

Publications (1)

Publication Number Publication Date
AU2005206410A1 true AU2005206410A1 (en) 2005-08-04

Family

ID=34805423

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005206410A Abandoned AU2005206410A1 (en) 2004-01-22 2005-01-20 Method of producing minus strand RNA virus vector with the use of hybrid promoter containing cytomegalovirus enhancer and avian beta-actin promoter

Country Status (8)

Country Link
US (1) US8741650B2 (https=)
EP (2) EP2434020B1 (https=)
JP (2) JP4999330B2 (https=)
KR (1) KR101279677B1 (https=)
CN (1) CN1934260B (https=)
AU (1) AU2005206410A1 (https=)
CA (1) CA2553976C (https=)
WO (1) WO2005071092A1 (https=)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0863202T3 (da) * 1995-11-01 2010-09-27 Dnavec Research Inc Rekombinant Sendai-virus
US20030166252A1 (en) * 1999-05-18 2003-09-04 Kaio Kitazato Paramyxovirus-derived RNP
AU2003234775A1 (en) * 2002-04-30 2003-11-17 Dnavec Research Inc. Vector with modified protease-dependent tropism
WO2005042737A1 (ja) * 2003-11-04 2005-05-12 Dnavec Research Inc. 遺伝子導入された樹状細胞の製造方法
WO2006001120A1 (ja) * 2004-06-24 2006-01-05 Dnavec Research Inc. マイナス鎖rnaウイルスを含む抗癌剤
WO2006134917A1 (ja) 2005-06-14 2006-12-21 Dnavec Corporation 抗体の作製方法
CA2636600A1 (en) * 2006-01-17 2007-07-26 Dnavec Corporation Novel protein expression system
CA2654033A1 (en) 2006-05-31 2007-12-06 Dnavec Corporation Therapeutic agent for alzheimer's disease
KR20090052857A (ko) 2006-07-13 2009-05-26 디나벡크 가부시키가이샤 비복제형 파라믹소바이러스과 바이러스 벡터
KR100725023B1 (ko) * 2006-10-16 2007-06-07 제일모직주식회사 카도계 수지를 함유한 수지 조성물 및 그에 의한 패턴의 제조방법, 이를 이용한 컬러필터
JPWO2008096811A1 (ja) 2007-02-07 2010-05-27 ディナベック株式会社 弱毒化マイナス鎖ｒｎａウイルス
US20100203027A1 (en) 2007-04-27 2010-08-12 Kyushu Univeristy National University Viral vector for gene therapy
US9127256B2 (en) 2008-07-16 2015-09-08 Dnavec Corporation Method for production of reprogrammed cell using chromosomally unintegrated virus vector
US8663981B2 (en) 2008-08-07 2014-03-04 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health Optimized promoter sequence
JPWO2010050586A1 (ja) 2008-10-31 2012-03-29 ディナベック株式会社 組み換え蛋白質の発現を増強する方法
CA2809515A1 (en) 2010-08-30 2012-03-08 Dnavec Corporation Composition for inducing pluripotent stem cell, and use thereof
CN102436142B (zh) 2010-09-29 2013-11-06 第一毛织株式会社 黑色光敏树脂组合物以及使用其的光阻层
KR101367253B1 (ko) 2010-10-13 2014-03-13 제일모직 주식회사 감광성 수지 조성물 및 이를 이용한 차광층
KR101038126B1 (ko) 2010-11-30 2011-05-31 주식회사 엘지생명과학 새로운 융합 프로모터 및 이를 포함하는 재조합 벡터
CN102028943A (zh) * 2010-12-08 2011-04-27 中国人民解放军军事医学科学院微生物流行病研究所 一种呼吸道合胞病毒样颗粒疫苗及其制备方法
KR101486560B1 (ko) 2010-12-10 2015-01-27 제일모직 주식회사 감광성 수지 조성물 및 이를 이용한 차광층
KR101453769B1 (ko) 2010-12-24 2014-10-22 제일모직 주식회사 감광성 수지 조성물 및 이를 이용한 컬러 필터
US20130325376A1 (en) 2011-04-07 2013-12-05 Thomas Edwin Turicchi, Jr. Systems and methods for determining a power phase and/or a phase rotation
KR101344786B1 (ko) 2011-12-02 2013-12-26 제일모직주식회사 컬러필터용 감광성 수지 조성물 및 이를 이용한　컬러필터
FR2986536A1 (fr) * 2012-02-08 2013-08-09 Lfb Biotechnologies Unites de transcription et leur utilisation dans des vecteurs d'expression (cho)
DK2711426T3 (en) * 2012-09-24 2015-07-13 Lonza Biologics Plc Expression vectors comprising chimeric cytomegalovirus promoter and enhancer sequences
KR20140076320A (ko) 2012-12-12 2014-06-20 제일모직주식회사 감광성 수지 조성물 및 이를 이용한 블랙 스페이서
US9828609B2 (en) 2013-03-12 2017-11-28 International Park Of Creativity Biological devices and methods for increasing the production of lycopene from plants
US10975358B2 (en) 2013-09-24 2021-04-13 Id Pharma Co., Ltd. Method for improving efficiency of inducing pluripotent stem cell
FI3628334T3 (fi) 2014-03-21 2023-09-15 Genzyme Corp Geenihoito verkkokalvon pigmenttirappeuma
CN104404005A (zh) * 2014-12-22 2015-03-11 天津瑞普生物技术股份有限公司 禽流感病毒ha基因重组腺病毒的制备方法
JP7150241B2 (ja) 2016-11-17 2022-10-11 国立感染症研究所長 非感染性パラミクソウイルス粒子を用いた感染症ワクチン
AU2018261769B2 (en) 2017-05-05 2024-03-14 The Regents Of The University Of California Compositions and methods for expressing Otoferlin
JP6947825B2 (ja) 2017-07-21 2021-10-13 株式会社 アイロムグループ 標的配列を改変するためのポリヌクレオチドおよびその使用
AU2018306455A1 (en) 2017-07-26 2020-02-27 Virogin Biotech Canada Ltd Oncolytic viral vectors and uses thereof
EP3744847A4 (en) 2018-01-22 2021-12-08 Japan as Represented by The Director-General of National Institute of Infectious Diseases SELECTIVE CD8 POSITIVE T CELL INDUCING VACCINE ANTIGEN
US12188041B2 (en) 2018-11-01 2025-01-07 University Of Florida Research Foundation, Incorporated Codon optimized otoferlin AAV dual vector gene therapy
EP3921032A4 (en) 2019-02-08 2022-11-30 Decibel Therapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF SENSORINEURAL HEARING LOSS USING OTOFERLIN DOUBLE VECTOR SYSTEMS
CN109929847B (zh) * 2019-02-27 2023-08-15 苏州系统医学研究所 一种pex26基因、蛋白及其应用
CN114040979B (zh) * 2019-06-21 2024-06-28 国立大学法人大阪大学 稳定地保持外源基因的人工重组rna病毒的制作方法
CA3157063A1 (en) * 2019-10-10 2021-04-15 Oncorus, Inc. Dual viruses and dual oncolytic viruses and methods of treatment
CA3159549A1 (en) 2019-10-30 2021-05-06 Decibel Therapeutics, Inc. Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems
AU2021247172A1 (en) 2020-04-01 2022-09-15 University Of Florida Research Foundation, Incorporated Dual AAV-MY07A vectors with improved safety for the treatment of USH1B
EP4209593A4 (en) 2020-09-04 2024-10-09 Heartseed Inc. IPS CELL QUALITY IMPROVING AGENT, METHOD FOR PRODUCING IPS CELLS, IPS CELLS, AND COMPOSITION FOR PRODUCING IPS CELLS
JPWO2022138964A1 (https=) 2020-12-25 2022-06-30
EP4365298A4 (en) 2021-06-30 2025-09-10 Repli Tech Co Ltd METHOD FOR PRODUCING NEGATIVE-STRANDED RNA VIRUS VECTOR AND PRODUCED NEGATIVE-STRANDED RNA VIRUS VECTOR
CN115772520B (zh) * 2021-09-08 2023-11-21 北京锦篮基因科技有限公司 用于治疗庞贝氏病的基因治疗构建体、药物组合物和方法
WO2023127871A1 (ja) 2021-12-27 2023-07-06 株式会社レプリテック 温度感受性のマイナス鎖ｒｎａウイルスまたはウイルスベクターおよびそのｒｎａゲノム
JPWO2024195811A1 (https=) 2023-03-22 2024-09-26
CN117051040B (zh) * 2023-08-15 2024-10-01 北京百普赛斯生物科技股份有限公司 Vsv△g复制缺陷型病毒制备及应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU629554B2 (en) * 1988-06-24 1992-10-08 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Exogenous gene expression vector containing chick beta-actin gene promoter
JP2824434B2 (ja) 1989-11-28 1998-11-11 財団法人化学及血清療法研究所 新規発現ベクター
JP2001283451A (ja) 1992-05-13 2001-10-12 Matsushita Electric Ind Co Ltd 記録方法および再生方法
JPH06230752A (ja) 1992-09-14 1994-08-19 Hitachi Ltd 表示装置の駆動方法
JPH06230753A (ja) 1993-01-29 1994-08-19 Fuji Xerox Co Ltd 画像処理装置
JPH06233879A (ja) 1993-02-08 1994-08-23 Brother Ind Ltd ロックミシンのかがり方式変換装置
US5798100A (en) 1994-07-06 1998-08-25 Immunomedics, Inc. Multi-stage cascade boosting vaccine
DK0864645T3 (da) * 1995-10-31 2005-10-24 Dnavec Research Inc Negativstrenget RNA-virusvektor med autonom replikeringsaktivitet
DK0863202T3 (da) * 1995-11-01 2010-09-27 Dnavec Research Inc Rekombinant Sendai-virus
EP0884383A4 (en) 1996-02-29 2001-12-05 Takara Shuzo Co METHOD FOR CLEANING AND REMOVING VIRUSES.
US6596529B1 (en) * 1997-05-02 2003-07-22 Uab Research Foundation Manipulation of negative stranded RNA viruses by rearrangement of their genes and uses thereof
US6187994B1 (en) 1997-11-18 2001-02-13 Pioneer Hi-Bred International, Inc. Compositions and methods for genetic modification of plants
DE69925841T2 (de) 1998-08-11 2006-05-11 Dnavec Research Inc., Tsukuba Rns virus vektor mit der fähigkeit zur kontaktinfiltration
US20030166252A1 (en) * 1999-05-18 2003-09-04 Kaio Kitazato Paramyxovirus-derived RNP
US20020169306A1 (en) * 1999-05-18 2002-11-14 Kaio Kitazato Envelope gene-deficient paramyxovirus vector
US20030022376A1 (en) * 1999-05-18 2003-01-30 Kaio Kitazato Paramyxovirus-derived RNP
KR100739938B1 (ko) 1999-05-18 2007-07-16 가부시키가이샤 디나벡크 겐큐쇼 엔벨로프 유전자 결손 파라믹소과 바이러스 벡터
US7226786B2 (en) * 1999-05-18 2007-06-05 Dnavec Research Inc. Envelope gene-deficient Paramyxovirus vector
ATE399206T1 (de) 1999-05-18 2008-07-15 Dnavec Research Inc Ribonukleoproteinkomplex aus paramyxovirus
EP1067179A1 (en) 1999-07-09 2001-01-10 Pierre Fabre Medicament Method to select attenuated paramyxoviridae useful for vaccines and therapeutics
EP1211318B1 (en) 1999-09-06 2007-08-08 DNAVEC Research, Inc. Paramyxoviruses comprising a modified transcription start sequence
JP4791651B2 (ja) 2000-05-18 2011-10-12 株式会社ディナベック研究所 外来遺伝子導入用パラミクソウイルスベクター
JPWO2003025570A1 (ja) 2001-09-18 2004-12-24 株式会社ディナベック研究所 粒子形成能が低下した（−）鎖ｒｎａウィルスベクターの検査方法および製造方法
AU2003234775A1 (en) * 2002-04-30 2003-11-17 Dnavec Research Inc. Vector with modified protease-dependent tropism
WO2006001120A1 (ja) * 2004-06-24 2006-01-05 Dnavec Research Inc. マイナス鎖rnaウイルスを含む抗癌剤
AU2006237903A1 (en) * 2005-04-20 2006-10-26 Dna Vec Corporation Highly safe intranasally administrable gene vaccines for treating Alzheimer's disease
CA2654033A1 (en) * 2006-05-31 2007-12-06 Dnavec Corporation Therapeutic agent for alzheimer's disease

Also Published As

Publication number Publication date
EP1717317A4 (en) 2009-02-11
KR20070004636A (ko) 2007-01-09
EP2434020A2 (en) 2012-03-28
CA2553976A1 (en) 2005-08-04
JP4999330B2 (ja) 2012-08-15
JP2012130346A (ja) 2012-07-12
US20070161110A1 (en) 2007-07-12
CA2553976C (en) 2013-09-24
CN1934260B (zh) 2013-03-13
EP2434020B1 (en) 2014-11-05
CN1934260A (zh) 2007-03-21
WO2005071092A1 (ja) 2005-08-04
JP5438149B2 (ja) 2014-03-12
EP1717317A1 (en) 2006-11-02
JPWO2005071092A1 (ja) 2007-09-06
US8741650B2 (en) 2014-06-03
KR101279677B1 (ko) 2013-06-27
EP2434020A3 (en) 2012-07-25

Similar Documents

Publication Publication Date Title
US8741650B2 (en) Methods for producing minus-strand RNA viral vectors using hybrid promoter comprising cytomegalovirus enhancer and chicken β-actin promoter
JP3602058B2 (ja) エンベロープ遺伝子欠損パラミクソ科ウイルスベクター
US7144579B2 (en) Paramyxoviruses comprising modified transcription start sequence
EP1179594B1 (en) Ribonucleoprotein complex in paramyxovirus
US6746860B1 (en) Paramyxovirus vectors used for transfer of foreign genes
US20070009949A1 (en) Paramyxovirus-derived RNP
US20060104950A1 (en) Methods of Tranducing genes into T cells
KR20090114431A (ko) 약독화 마이너스 가닥 ｒｎａ 바이러스
US20030022376A1 (en) Paramyxovirus-derived RNP
JP4791651B2 (ja) 外来遺伝子導入用パラミクソウイルスベクター
EP1642966B1 (en) Minus strand rna viral vectors carrying a gene with altered hypermutable regions
US20060216824A1 (en) Paramyxovirus vector encoding ribozyme and utilization thereof
WO2006137517A1 (ja) 幼少個体への遺伝子導入用ベクター
HK1094898A (en) Methods for producing minus-strand rna viral vectors using hybrid promoter comprising cytomegalovirus enhancer and chicken beta-actin promoter
HK1083110A (en) Paramyxovirus vector encoding ribozyme and utilization thereof
HK1078108A (en) Method of transferring gene into t cells

Legal Events

Date Code Title Description
MK3 Application lapsed section 142(2)(c) - examination deferred under section 46 no request for examination